342 related articles for article (PubMed ID: 18473757)
1. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
Stonehouse A; Okerson T; Kendall D; Maggs D
Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757
[TBL] [Abstract][Full Text] [Related]
2. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
3. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ
Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Verspohl EJ
Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590
[TBL] [Abstract][Full Text] [Related]
6. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
7. Combination pharmacotherapy with incretins: what works best and when?
Over RK; Ratner RE
Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
[TBL] [Abstract][Full Text] [Related]
8. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Davidson JA; Parente EB; Gross JL
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
[TBL] [Abstract][Full Text] [Related]
9. Management of Type 2 diabetes: the role of incretin mimetics.
Stonehouse AH; Holcombe JH; Kendall DM
Expert Opin Pharmacother; 2006 Oct; 7(15):2095-105. PubMed ID: 17020435
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
[TBL] [Abstract][Full Text] [Related]
11. Incretin physiology and its role in type 2 diabetes mellitus.
Svec F
J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
13. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic role of incretin mimetics and DPP-4 inhibitors.
Funnell MM
Diabetes Educ; 2009; 35 Suppl 1():12S-7S. PubMed ID: 19218562
[TBL] [Abstract][Full Text] [Related]
15. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
Kendall DM; Kim D; Maggs D
Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes.
Blevins T
Postgrad Med; 2010 Jan; 122(1):172-83. PubMed ID: 20107301
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Nicolucci A; Rossi MC
Acta Biomed; 2008 Dec; 79(3):184-91. PubMed ID: 19260377
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S10-9. PubMed ID: 20824235
[TBL] [Abstract][Full Text] [Related]
19. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
Mudaliar S; Henry RR
Am J Med; 2010 Mar; 123(3 Suppl):S19-27. PubMed ID: 20206728
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in incretin-based therapies.
Russell-Jones D; Gough S
Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
